 DELRAY BEACH, Fla., Nov. 30, 2020 GLOBE NEWSWIRE -- AzurRx BioPharma, Inc. NASDAQ:AZRX AzurRx or the Company, a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced that the first two patients have been dosed in Turkey for its Phase 2 trial evaluating its investigational drug, MS1819, in combination with the current standard of care, porcine-derived pancreatic enzyme replacement therapy PERT, for the treatment of severe exocrine pancreatic insufficiency EPI in patients with cystic fibrosis CF. 